Pharmacokinetics of β-Alanine Using Different Dosing Strategies

Introduction: The ergogenic response following long-term ingestion of β-alanine shows a high inter-individual variation. It is hypothesized that this variation is partially caused by a variable pharmacokinetic response induced by inferior dosing strategies. At this point most supplements are either...

Full description

Bibliographic Details
Main Authors: Jan Stautemas, Inge Everaert, Filip B. D. Lefevere, Wim Derave
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-08-01
Series:Frontiers in Nutrition
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fnut.2018.00070/full
id doaj-8d82ef31bdf141e099036e3883a536c9
record_format Article
spelling doaj-8d82ef31bdf141e099036e3883a536c92020-11-25T00:54:30ZengFrontiers Media S.A.Frontiers in Nutrition2296-861X2018-08-01510.3389/fnut.2018.00070389572Pharmacokinetics of β-Alanine Using Different Dosing StrategiesJan StautemasInge EveraertFilip B. D. LefevereWim DeraveIntroduction: The ergogenic response following long-term ingestion of β-alanine shows a high inter-individual variation. It is hypothesized that this variation is partially caused by a variable pharmacokinetic response induced by inferior dosing strategies. At this point most supplements are either taken in a fixed amount (× g), as is the case with β-alanine, or relative to body weight (× g per kg BW), but there is currently neither consensus nor a scientific rationale on why these or other dosing strategies should be used. The aim of this study is to objectify and understand the variation in plasma pharmacokinetics of a single oral β-alanine dose supplemented as either a fixed or a weight-relative dose (WRD) in an anthropometric diverse sample.Methods: An anthropometric diverse sample ingested a fixed dose (1,400 mg) (n = 28) and a WRD of β-alanine (10 mg/kg BW) (n = 34) on separate occasions. Blood samples were taken before and at nine time points (up to 4 h) after β-alanine ingestion in order to establish a pharmacokinetic profile. Incremental area under the curve (iAUC) was calculated by the trapezoidal rule. Plasma β-alanine was quantified using HPLC-fluorescence.Results: The variation coefficient (CV%) of the iAUC was 35.0% following ingestion of 1,400 mg β-alanine. Body weight explained 30.1% of the variance and was negatively correlated to iAUC (r = −0.549; p = 0.003). Interestingly, the CV% did not decrease with WRD (33.2%) and body weight was positively correlated to iAUC in response to the WRD (r = 0.488; p = 0.003).Conclusion: Both dosing strategies evoked an equally high inter-individual variability in pharmacokinetic plasma profile. Strikingly, while body weight explained a relevant part of the variation observed following a fixed dose, correction for body weight did not improve the homogeneity in β-alanine plasma response. We suggest to put more effort into the optimization of easy applicable and scientifically justified personalized dosing strategies.https://www.frontiersin.org/article/10.3389/fnut.2018.00070/fullβ-alaninesports supplementspharmacokineticspersonalized nutritioncarnosine
collection DOAJ
language English
format Article
sources DOAJ
author Jan Stautemas
Inge Everaert
Filip B. D. Lefevere
Wim Derave
spellingShingle Jan Stautemas
Inge Everaert
Filip B. D. Lefevere
Wim Derave
Pharmacokinetics of β-Alanine Using Different Dosing Strategies
Frontiers in Nutrition
β-alanine
sports supplements
pharmacokinetics
personalized nutrition
carnosine
author_facet Jan Stautemas
Inge Everaert
Filip B. D. Lefevere
Wim Derave
author_sort Jan Stautemas
title Pharmacokinetics of β-Alanine Using Different Dosing Strategies
title_short Pharmacokinetics of β-Alanine Using Different Dosing Strategies
title_full Pharmacokinetics of β-Alanine Using Different Dosing Strategies
title_fullStr Pharmacokinetics of β-Alanine Using Different Dosing Strategies
title_full_unstemmed Pharmacokinetics of β-Alanine Using Different Dosing Strategies
title_sort pharmacokinetics of β-alanine using different dosing strategies
publisher Frontiers Media S.A.
series Frontiers in Nutrition
issn 2296-861X
publishDate 2018-08-01
description Introduction: The ergogenic response following long-term ingestion of β-alanine shows a high inter-individual variation. It is hypothesized that this variation is partially caused by a variable pharmacokinetic response induced by inferior dosing strategies. At this point most supplements are either taken in a fixed amount (× g), as is the case with β-alanine, or relative to body weight (× g per kg BW), but there is currently neither consensus nor a scientific rationale on why these or other dosing strategies should be used. The aim of this study is to objectify and understand the variation in plasma pharmacokinetics of a single oral β-alanine dose supplemented as either a fixed or a weight-relative dose (WRD) in an anthropometric diverse sample.Methods: An anthropometric diverse sample ingested a fixed dose (1,400 mg) (n = 28) and a WRD of β-alanine (10 mg/kg BW) (n = 34) on separate occasions. Blood samples were taken before and at nine time points (up to 4 h) after β-alanine ingestion in order to establish a pharmacokinetic profile. Incremental area under the curve (iAUC) was calculated by the trapezoidal rule. Plasma β-alanine was quantified using HPLC-fluorescence.Results: The variation coefficient (CV%) of the iAUC was 35.0% following ingestion of 1,400 mg β-alanine. Body weight explained 30.1% of the variance and was negatively correlated to iAUC (r = −0.549; p = 0.003). Interestingly, the CV% did not decrease with WRD (33.2%) and body weight was positively correlated to iAUC in response to the WRD (r = 0.488; p = 0.003).Conclusion: Both dosing strategies evoked an equally high inter-individual variability in pharmacokinetic plasma profile. Strikingly, while body weight explained a relevant part of the variation observed following a fixed dose, correction for body weight did not improve the homogeneity in β-alanine plasma response. We suggest to put more effort into the optimization of easy applicable and scientifically justified personalized dosing strategies.
topic β-alanine
sports supplements
pharmacokinetics
personalized nutrition
carnosine
url https://www.frontiersin.org/article/10.3389/fnut.2018.00070/full
work_keys_str_mv AT janstautemas pharmacokineticsofbalanineusingdifferentdosingstrategies
AT ingeeveraert pharmacokineticsofbalanineusingdifferentdosingstrategies
AT filipbdlefevere pharmacokineticsofbalanineusingdifferentdosingstrategies
AT wimderave pharmacokineticsofbalanineusingdifferentdosingstrategies
_version_ 1725234092476203008